Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Clonazepam belongs to a group of medicines called benzodiazepines. It works by boosting the activity of a naturally occurring chemical messenger in the brain called GABA (gamma-aminobutyric acid). When GABA binds to receptors on nerve cells, clonazepam strengthens that signal, which allows more chloride ions to flow into the cells. This slows down nerve activity across the central nervous system, producing effects that include reducing seizures, relaxing muscles, and calming anxiety.
The medication is approved in Australia for treating several types of epilepsy. In infants and children, it's used for absence seizures (sometimes called petit mal), myoclonic seizures, and tonic-clonic fits. In adults, it's used for all varieties of generalised epilepsy—including myoclonic, akinetic, tonic, and tonic-clonic seizures—as well as partial epilepsy, which includes psychomotor seizures. It can also be given by injection to stop status epilepticus, a medical emergency involving prolonged seizures. Additionally, clonazepam is approved for use in patients receiving palliative care.
Clonazepam stays in the body for quite a while. Its half-life—the time it takes for half the dose to be eliminated—ranges from 19 to 60 hours, with an average around 39 hours. This means the medication builds up gradually when taken regularly and takes several days to clear after stopping. The liver breaks down clonazepam using enzymes, including one called CYP3A4. Medications that block CYP3A4, such as the antifungal fluconazole, can slow this breakdown and lead to higher levels of clonazepam in the body, which may increase its effects.
Side effects occur relatively frequently and include impaired concentration, drowsiness, slowed reactions, muscle weakness, dizziness, and problems with balance and coordination (ataxia). Fatigue and a feeling of low muscle tone are also common. Some people experience vertigo or increased mucus production in the airways. More serious effects are possible, though the source data doesn't specify how often they occur. These include breathing problems—particularly when clonazepam is given by injection—heart failure or cardiac arrest, severe allergic reactions (anaphylaxis), coma, and suicidal attempts.
Your family member should not take clonazepam if they have a known allergy to it, to other benzodiazepines, or to any of the inactive ingredients in the tablets or injection. It's also contraindicated in people with chronic lung disease where breathing failure is developing, severe liver impairment (because benzodiazepines can trigger a dangerous condition called hepatic encephalopathy), or dependence on alcohol or other central nervous system depressants.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationEpilepsy Clinical criteria: The condition must be neurologically proven. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“Benzodiazepines enhance the polysynaptic inhibitory processes at all levels of the central nervous system.”
“The mean elimination half-life is 39.0 ± 8.3 hours.”
“The enzymes involved in the metabolism of Rivotril have not been clearly identified but include CYP3A4. Inhibitors of CYP3A4 (e.g., fluconazole) may impair the metabolism of Rivotril and lead to exaggerated concentrations and effects.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Clonazepam is a benzodiazepine derivative that enhances the activity of gamma-aminobutyric acid at central GABA receptors, increasing chloride influx and producing anticonvulsant, anxiolytic, and muscle-relaxant effects through enhanced inhibitory neurotransmission. It carries TGA-approved indications for most types of epilepsy in infants and children—including absences, myoclonic seizures, and tonic-clonic fits—and for all varieties of generalised and partial epilepsy in adults. Intravenous administration is indicated for status epilepticus, and the oral formulation is listed for use in patients receiving palliative care.
The mean elimination half-life is approximately 39 hours, with a reported range of 19–60 hours. Metabolism involves CYP3A4, and co-administration with CYP3A4 inhibitors such as fluconazole may impair clearance and lead to exaggerated plasma concentrations and clinical effects. Clonazepam is contraindicated in patients with known hypersensitivity to benzodiazepines, chronic obstructive airways disease with incipient respiratory failure, severe hepatic impairment, and dependence on drugs of abuse or CNS depressants including alcohol.
Common adverse effects include impaired concentration, drowsiness, somnolence, slowed reaction time, muscular hypotonia, dizziness, ataxia, muscle weakness, fatigue, vertigo, and bronchial hypersecretion. Serious adverse effects include respiratory depression—particularly with intravenous administration—cardiac failure including cardiac arrest, anaphylaxis, suicidal attempt, and coma.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.